Collegium Pharmaceutical Reports Record Q2 2025 Revenue

Collegium Pharmaceutical ( (COLL) ) has provided an update.

On August 7, 2025, Collegium Pharmaceutical reported its financial results for the second quarter of 2025, showcasing a record quarterly net revenue of $188.0 million, a 29% increase year-over-year. The company raised its full-year 2025 revenue guidance to $745-$760 million and adjusted EBITDA guidance to $440-$455 million. Notably, Jornay PM net revenue reached $32.6 million, with prescriptions growing by 23% year-over-year. The pain portfolio also saw a 7% revenue increase. Collegium announced a $150 million share repurchase program and completed a $25 million accelerated share repurchase, emphasizing its focus on enhancing shareholder value.

The most recent analyst rating on (COLL) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.

Spark’s Take on COLL Stock

According to Spark, TipRanks’ AI Analyst, COLL is a Outperform.

Collegium Pharmaceutical’s strong financial performance, strategic initiatives, and positive earnings call sentiment contribute significantly to its stock score. However, high leverage and valuation concerns moderate the overall outlook.

To see Spark’s full report on COLL stock, click here.

More about Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions. The company has a strong portfolio in responsible pain management medications and a growing neuropsychiatry business, primarily driven by Jornay PM®, a treatment for ADHD. Collegium’s strategy involves expanding its commercial portfolio and disciplined capital deployment.

Average Trading Volume: 297,034

Technical Sentiment Signal: Hold

Current Market Cap: $999.6M

Find detailed analytics on COLL stock on TipRanks’ Stock Analysis page.